louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02167672: Barriers for the Uptake of LaparoScopic Hysterectomy
Official title: What Would it Take to Reduce the Proportion of Women Who Have a Hysterectomy Via an Open Abdominal Approach in Australia?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hysterectomy
Keywords: total abdominal hysterectomy, total laparoscopic hysterectomy, vaginal hysterectomy
Lead sponsor: Queensland Centre for Gynaecological Cancer
Sponsor class: OTHER_GOV
Collaborators: name: Queensland University of Technology
First posted: 2014-06-19
Enrollment: 1200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Members of RANZCOG community sample

Brief summary: Hysterectomy (surgical removal of the uterus) is the most common major gynaecological operation in women in developed countries. In Queensland, 6000 women require a hysterectomy for irregular periods, benign tumours or pelvic pain every year. Surgical approaches to surgical removal of the uterus (womb) include Laparoscopic Hysterectomy (LH), Vaginal Hysterectomy (VH) and Abdominal Hysterectomy through an abdominal incision (AH).

It is widely accepted that LH and VH are less invasive surgical procedures, cause less bleeding, surgical complications and pain and are associated with quicker recovery from surgery than the more invasive AH. In a clinical trial comparing LH and AH we recently demonstrated that LH outperforms AH with regards to cost effectiveness causing less total health-services cost than AH.

Implementation of LH in Queensland could save $9.8 million every year. Despite the evidence for LH and VH, 2600 hysterectomies (43%) are still performed through an open, abdominal incision. In brief, a common but outdated operation is still performed regularly causing not only unnecessary pain, surgical adverse events and longer hospital stay but also increased healthcare costs.

This study will assess reasons why a significant number of gynaecologists and patients prefer AH over LH (Barriers to the uptake of laparoscopic hysterectomy). We will survey specialist gynaecologists as well as patients who have had a hysterectomy for different health reasons. Based on the information from the survey the investigators will develop an intervention to increase the rate of laparoscopic hysterectomies in Queensland and pilot test it.


Eligibility criteria: Inclusion Criteria:

* Obstetricians and Gynaecologists or Women who have had a hysterectomy in the previous 2 years

Exclusion Criteria:

* Women who have had a hysterectomy more than 2 years ago
* Women who had a hysterectomy for cancerous conditions

Primary outcomes:
measure: Questionnaire will identify barriers
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: University of Queensland
state: Queensland
Study officials:
affiliation: Queensland Health
name: Andreas Obermair
role: STUDY_CHAIR
References:
Clinical trial NCT05812872: Alveolar Ridge Preservation Using Different Bone Substitutes
Official title: The Effect of Allograft, Toothgraft, Alloplast on Alveolar Ridge Preservation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Alveolar Ridge Enlargement
Keywords: Alveolar ridge preservation, Allograft, Toothgraft, Allopast
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2023-04-14
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study was to compare the efficacy of using allograft, autogenous tooth graft, and beta-tricalcium phosphate for alveolar ridge preservation (ARP) by examining the alveolar ridge height and width at baseline and 3 months after the ARP both clinically and radiographically. The secondary objective was to evaluate the quality of the newly formed bone using histomorphometric analysis.

Detailed description: This randomized controlled clinical trial included thirty patients. ARP was performed using either Allograft (Allograft group n=10), Tooth graft (Toothgraft group n=10), and beta tri-calcium- phosphate (beta tri-calcium group n=10). Changes in alveolar ridge dimensions were evaluated clinically and radiographically using cone beam computed tomography at baseline and 3 months. Core bone biopsy samples were obtained 3 months post-extraction during implant placement for histomorphometric analysis.

Eligibility criteria: Inclusion Criteria:

1. seeking implant-based restorations after tooth extraction.
2. exhibited no evidence of any significant medical history, measured using Burket's Oral medicine health history questionnaire.
3. exhibited Type I and II sockets

Exclusion Criteria:

1. nonsmokers.
2. Pregnant and breast-feeding females
3. patients with known contraindications to dental implant surgery (e.g., increased bleeding tendency, history of treatments such as radiotherapy,

Primary outcomes:
measure: Clinical assessment
timeFrame: 3 months
measure: Clinical assessment
timeFrame: 3 months
Secondary outcomes:
measure: Radiographic assessment
timeFrame: 3 months
measure: Radiographic assessment
timeFrame: 3 months
Other outcomes:
measure: Histological
timeFrame: 3 months
measure: Histomorphometric analysis
timeFrame: 3 months
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
affiliation: Ain Shams University
name: Yasmine A Fouad, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Ain Shams University
name: Suzan M Sarhan, Ph.D
role: STUDY_DIRECTOR
affiliation: Ain Shams University
name: Hadeel M Gamal, Ph.D
role: STUDY_DIRECTOR
affiliation: Ain Shams University
name: Basma A Abdelrahman, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02027272: Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):
Official title: Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Eclampsia
Keywords: Eclampsia
Lead sponsor: University of Mississippi Medical Center
Sponsor class: OTHER
First posted: 2014-01-06
Enrollment: 1
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or steroid will receive standard therapy to include magnesium sulfate, blood pressure medications and diuretics. We hypothesize that the addition of dexamethasone to standard therapy will accelerate CNS recovery more quickly than standard management without dexamethasone.

Detailed description: 30 eclamptic patients who do not require steroids for fetal lung maturation purposes will be randomized to placebo or steroid. This includes patients with eclampsia encountered antepartum prior to 23 weeks gestation, postpartum eclampsia, undelivered patients encountered after 33 weeks gestation who would not be candidates for fetal lung maturation steroids, or patients not eligible for repeat steroid administration in the 23-34 week gestational window. Planned enrollment in this pilot study is up to 30 patients with at least 12 in each group.

Eligibility criteria: Inclusion Criteria:

1. Currently 34 weeks pregnant or within 6 weeks postpartum
2. At least 18 years of age
3. Singleton or twin gestation
4. Patient or family sign informed consent
5. Diagnosis of eclampsia
6. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure

Exclusion Criteria:

1. Neither pregnant nor within first 6 weeks postpartum
2. Patient or family unable to sign informed consent
3. Less than 18 years of age
4. Triplet or higher order gestation
5. Unable to obtain MRI scanning within 24 hours of hospital admission (
6. Diagnosis of cerebral hemorrhage
7. Patient in whom MRI is contraindicated

Primary outcomes:
measure: Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
Study officials:
affiliation: University of Mississippi Medican Center
name: James Martin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03589872: The Fine Motor Dexterity Under Dual Task in Parkinson's Disease
Official title: The Contribution of the Dual Task Interference on the Dexterity Related Activities of Daily Living in Parkinson's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fine Motor Skill Dysfunction
Parkinson Disease
Keywords: hand function, dual task, Parkinson disease, activities of daily living
Lead sponsor: T.C. ORDU ÜNİVERSİTESİ
Sponsor class: OTHER
First posted: 2018-07-18
Enrollment: 53
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: community sample:community-dwelling patients with Parkinson disease.

Brief summary: This study was planned to investigate the contribution of dual task interference on dexterity related ADL disability in patients with Parkinson's disease. We hypothesised that the dual task interference is an indicator of dexterity related ADL difficulties.

Detailed description: We planned this study as a cross sectional trial. 53 patients with Parkinson's disease will be evaluated under 2 different task by nine hole peg test. Besides this assessment the cardinal symptoms (bradykinesia, tremor, rigidity) will be evaluated to determine their contribution on the ADL performance.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of idiopathic Parkinson's disease according to the criteria of the United Kingdom brain Bank by neurologist
* Age 50-90 range
* having sufficient cognitive status according to the Mini Mental Status Evaluation (24 or above from the Mini Mental Test)

Exclusion Criteria:

* Having orthopedic and neurological disorders affecting hand function,
* Having sensory problems,
* Having Diabetus mellitus

Primary outcomes:
measure: Nine hole peg test
timeFrame: 5 minutes
measure: ADL-related dexterity Questionnaire 24 (DextQ-24)
timeFrame: 10 minutes
Secondary outcomes:
measure: Modified Hoehn and Yahr Scale
timeFrame: 2 minutes
measure: Unified Parkinson's Disease Rating Scale (UPDRS) - Section of Activities of Daily Living (ADL)
timeFrame: 10 minutes
measure: Unified Parkinson's Disease Rating Scale (UPDRS) - Motor Section
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Ordu
country: Turkey
facility: Sevim ACARÖZ CANDAN
state: Altinordu
Study officials:
affiliation: Ordu University, Department of Physiotherapy and Rehabilitation
name: SEVİM ACARÖZ CANDAN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01646372: Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills?
Official title: Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills? A Simulation Based Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Long-term Retention of Advanced Cardiac Life Support Skills
Keywords: Medical Education
Cognitive Aid
Crisis Resource Management
Advanced Cardiac Life Support
Skills Retention
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: The Academy for Innovation in Medical Education
name: The Ottawa Hospital Academic Medical Association
First posted: 2012-07-20
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to investigate whether formal instruction on the use of cognitive aids in managing a crisis will result in better longterm retention of knowledge and skills. In particular, this study examines the impact of cognitive aid teaching on the Advanced Cardiac Life Support course.


Eligibility criteria: Inclusion Criteria:

* Post-graduate Medical trainee in departments of Anesthesia, Emergency Medicine, Critical Care, Family Medicine, Internal Medicine
* Has taken ACLS Course at least once

Exclusion Criteria:

* Never taken ACLS Course

Primary outcomes:
measure: ACLS Megacode Examination Scale Score
timeFrame: 6 months
Secondary outcomes:
measure: Anesthesia Non-Technical Skills Scale (ANTS)
timeFrame: 6 Months
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: The Ottawa Hospital
state: Ontario
Study officials:
References:
Clinical trial NCT03740672: Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline
Official title: Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline in Chinese Patients of Gynecologic Malignancies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gynecologic Cancer
Chemotherapy-induced Nausea and Vomiting
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2018-11-14
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who are given chemotherapy treatment for gynecologic malignancies are included.

Brief summary: This study aims to investigate the adherence to the antiemesis NCCN guideline in Chinese patients of gynecologic malignancies, who are given chemotherapy treatment. The risk of chemotherapy induced nausea and vomiting (CINV) is calculated by the questionnaire supported by the website "CINV Risk Assessment" (http://www.riskcinv.org/).


Eligibility criteria: Inclusion Criteria:

* Good performance status
* Aged 18 years or older
* Signed an approved informed consents

Exclusion Criteria:

* Not meeting all of the inclusion criteria

Primary outcomes:
measure: risk of chemotherapy induced nausea and vomiting
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Lei Li
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Lei Li, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03530072: Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients
Official title: Using Next Gen Sequencing to Identify Pediatric Patients With Febrile Neutropenia at Low Risk for Complications: A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neutropenia
Fever
Lead sponsor: Karius, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Stanford University
First posted: 2018-05-21
Enrollment: 15
Sex: ALL
Minimum age (years): 1
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children being admitted for inpatient treatment with fever and neutropenia.

Brief summary: Febrile neutropenia is a common complication in pediatric oncology patients. Standard of care requires admission of all patients for intravenous antibiotics until cultures are negative, patients are afebrile and there are signs of bone marrow recovery. This often results in prolonged hospital admissions with significant financial costs, decreased quality of life and potential secondary infections. More recent data suggests it may be possible to identify a "low risk" group that can be discharged prior to signs of bone marrow recovery. At this time, researchers have been unable to identify a model that is safe for early discharge across institutions.

Detailed description: 1. Conduct a pilot study to determine the feasibility of using the Karius Assay to risk stratify pediatric oncology patients admitted with febrile neutropenia. This will provide preliminary data for a larger study which would randomize patients to early discharge vs. usual care.
2. Evaluate the Klaasen and SPOG clinical decision rules with and without the Karius Assay to predict patients at low risk for adverse infectious outcomes during admission. Adverse infectious outcome will be defined as: positive blood or urine culture, radiographic evidence of infection, admission to the intensive care unit or death.
3. Model potential cost savings of early discharge for patients deemed low risk for an adverse infectious outcome.

Eligibility criteria: Inclusion Criteria:

1) Pediatric oncology patients, aged 1-22, treated at Lucile Packard Children's Hospital (LPCH)

Exclusion Criteria:

1. Relapsed disease
2. Acute lymphoblastic leukemia during induction
3. Acute myeloid leukemia during any phase of treatment
4. Philadelphia-chromosome positive ALL
5. Down syndrome
6. Patients who have received an allogeneic stem cell transplant.

Primary outcomes:
measure: Modeled sensitivity and specificity
timeFrame: 1 day of Discharge
Secondary outcomes:
measure: Modeled cost savings
timeFrame: 1 day of Discharge
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Lucille Packard Children's Hopsital
state: California
Study officials:
affiliation: Lucille Packard Children's Hospital/Stanford University
name: Catherine Aftandillian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05103072: Subthalamic Nucleus Stimulation With Directional Leads on Patients With Parkinson Disease at Fluctuations and Dyskinesia Stage
Official title: Subthalamic Nucleus Stimulation With Directional Leads on Patients With Parkinson Disease at Fluctuations and Dyskinesia Stage
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parkinson Disease
Subthalamic Nucleus Stimulation
Directional Electrodes
Keywords: Parkinson Disease
Subthalamic nucleus stimulation
directional electrodes
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2021-11-02
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: It is a non interventional retrospective study. Data were collected before and after surgery of subthalamic nucleus stimulation of patients with Parkinson Disease.

Brief summary: Patients with subthalamic nucleus have to go through a lot of examinations and tests, before and after surgery which is difficult, sometimes painful, for the patient.

The investigators used to chose the best plot of the leads for stimulation by a procedure long and exhausting for the patient and the examinator.

The investigators can chose the plot using a software (Guide Xt), which can delete the exhausting test.

The investigators would like to study the non inferiority of this tool to choose the best plot .


Eligibility criteria: Inclusion Criteria:

* age : \>18Y
* All patient with Parkinson disease eligible for sub thalamic surgery (CAPSIT criterias) in CHU AMIENS

Exclusion Criteria:

* patient doesn't consent

Primary outcomes:
measure: Increase of MDS UPDRS 3 score
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT06053372: Pediatric Apple Watch Study
Official title: Leveraging Wearable Technologies for Arrhythmia Detection in Children - The PAW (Pediatric Apple Watch) Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Arrhythmia in Children
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-09-25
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Specific Aim #1 - To determine the accuracy of Apple Watch ECG tracings heart rate in children.

Specific Aim #2 - To determine if extended monitoring with the Apple Watch can identify arrhythmia events that were not detected by short term clinical monitoring.


Eligibility criteria: Inclusion Criteria:

* All pediatric patients age 6 - 21 years undergoing clinically indicated arrhythmia monitoring
* Patients with developmental ability (as determined by patient and parents) to safely wear the Apple Watch and utilize the patient activated trigger buttons on both the clinical monitor and the Apple Watch.

Exclusion Criteria:

* Age \< 6 years. Those under 6 many not be able to safely use the watch and have the developmental ability (as gauged by clinician and parents) to utilize the trigger features on the watch and cardiac rhythm monitor.
* Inability to effectively utilize the triggered features of the monitor or watch
* Patients unable to utilize the Apple Watch.

Primary outcomes:
measure: Heart rate correlation
timeFrame: Up to 2 weeks
measure: Arrhythmia correlation
timeFrame: Up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Scott Ceresnak, MD
role: PRINCIPAL_INVESTIGATOR
References: